#PHARMA SCTORS

[shlipayadavblog]

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

Multinational drug major Boehringer Ingelheim (BI) has obtained ad-interim injunctions against four domestic pharmaceutical companies -- Eris Lifesciences, Emcure Pharma, Optimus Pharma and MSN Laboratories. These companies had launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name Trajenta.

The company also secured injunctions against Dr Reddy's Laboratories (DRL) and MSN Laboratories earlier for its diabetic drug Empagliflozin marketed as Jardiance in India.

Also, the company had secured an ad-interim injunction against Macleods Pharma for its Linagliptin drug, which was eventually made absolute.

"The recent injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and/or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing," BI said in a statement here.

[shlipayadavblog]

Near-term growth issues and cost pressure could impact Aurobindo Pharma

Pulled back by a weak showing in the US and EU markets and cost pressures, Aurobindo Pharma delivered a weaker-than-expected performance in the March quarter. The muted performance and near-term margin outlook led to a downward revision of earnings estimates of up to 15 per cent. The stock is down 4 per cent from highs in June and is underperforming the broader market. The direction going ahead will depend on the pace of approvals and uptick in the base business.

[shlipayadavblog]

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Two senior members of the promoter family of homegrown pharmaceutical major Cipla Ltd on Tuesday sold over 2 crore shares representing 2.5 per cent of total issued and paid-up share capital, the company said in a regulatory filing.

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday. Post this transaction, the promoter group will continue to hold 34.23 per cent in the company, Cipla Executive Vice Chairperson Samina Hamied said in a statement filed on the BSE.

The company, however, did not provide the value at which the shares were sold.

"The group remains fully committed and invested in the future of Cipla Ltd. The senior promoters, who are both in their 80s, intend to use the funds generated from this sale for personal purposes including philanthropy," she said, adding the promoter group does not plan to sell any further shares in the foreseeable future.

Cipla today is being led by the third generation of the founding family.

"As a family, we are fully committed to the organisation. I will continue to carry forward the Cipla legacy and drive the company into the future to achieve new goals and scale new heights," Samina Hamied said.